IN2014DN08632A - - Google Patents
Info
- Publication number
- IN2014DN08632A IN2014DN08632A IN8632DEN2014A IN2014DN08632A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A IN 8632DEN2014 A IN8632DEN2014 A IN 8632DEN2014A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A
- Authority
- IN
- India
- Prior art keywords
- production
- during
- eye drop
- chelating agent
- diquafosol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
In a diquafosol eye drop containing a chelating agent at a concentration of 0.0001 to 1% (w/v) the production of insoluble precipitates during storage which is usually observed in a diquafosol eye drop and the deterioration in filtering performane during a production process (a filter sterilization process) can be prevented. In a diquafosol eye drop containing a chelating agent the reduction in eye irritation and the improvement in preservative efficacy compared with those in a diquafosol eye drop that does not contain any chelating agent are observed. Therefore in the present invention stable physicochemical properties can be achieved during the course of production and distribution and during the course of storage by a patient and the reduction in eye irritation and the improvement in preservative efficacy are observed. Particularly in a diquafosol eye drop containing a chelating agent the deterioration in filtering performance during a production process (a filter sterilization process) is prevented. Therefore highly efficient filter sterilization can be achieved during the course of production which contributes to the reduction in production cost.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012069157 | 2012-03-26 | ||
| PCT/JP2013/058519 WO2013146649A1 (en) | 2012-03-26 | 2013-03-25 | Diquafosol-containing eye drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08632A true IN2014DN08632A (en) | 2015-05-22 |
Family
ID=49259901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8632DEN2014 IN2014DN08632A (en) | 2012-03-26 | 2013-03-25 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9486529B2 (en) |
| EP (2) | EP3431092A1 (en) |
| JP (6) | JP5625081B2 (en) |
| KR (5) | KR20190002751A (en) |
| CN (2) | CN113018259A (en) |
| AU (3) | AU2013241507A1 (en) |
| BR (1) | BR112014023402B1 (en) |
| CA (1) | CA2868390C (en) |
| DK (1) | DK2832359T3 (en) |
| EA (1) | EA028848B1 (en) |
| ES (1) | ES2702575T3 (en) |
| GE (1) | GEP20166470B (en) |
| HK (2) | HK1204922A1 (en) |
| HU (1) | HUE041671T2 (en) |
| IN (1) | IN2014DN08632A (en) |
| MX (1) | MX353874B (en) |
| MY (1) | MY169816A (en) |
| NZ (1) | NZ631041A (en) |
| PH (1) | PH12014501955A1 (en) |
| PL (1) | PL2832359T3 (en) |
| PT (1) | PT2832359T (en) |
| SG (2) | SG10201607872PA (en) |
| TR (1) | TR201820073T4 (en) |
| TW (4) | TWI692364B (en) |
| UA (1) | UA113981C2 (en) |
| WO (1) | WO2013146649A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169816A (en) | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| MX2016009049A (en) | 2014-01-10 | 2016-09-09 | Santen Pharmaceutical Co Ltd | Pharmaceutical composition containing pyridylamino acetic acid compound. |
| JP6104433B2 (en) * | 2015-06-05 | 2017-03-29 | 参天製薬株式会社 | Aqueous ophthalmic solution |
| BR112017013841A2 (en) * | 2014-12-25 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Water applying-eyewash liquid |
| WO2016195072A1 (en) * | 2015-06-05 | 2016-12-08 | 参天製薬株式会社 | Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens |
| JPWO2017002827A1 (en) | 2015-06-29 | 2018-04-26 | ヤマサ醤油株式会社 | Method for storing P1, P4-bis (5'-uridyl) tetraphosphate crystals |
| JP6688057B2 (en) * | 2015-12-01 | 2020-04-28 | 日水製薬株式会社 | Post-dyeing reagent for Gram stain and Gram stain method |
| KR20220163519A (en) * | 2018-02-28 | 2022-12-09 | 산텐 세이야꾸 가부시키가이샤 | Ophthalmic composition comprising diquafosol and cationic polymer |
| CN108403625A (en) * | 2018-04-11 | 2018-08-17 | 东莞解石医药科技有限公司 | A kind of four sodium eye drops of ophthalmic solution containing chelating agent |
| KR20240049646A (en) * | 2019-08-27 | 2024-04-16 | 산텐 세이야꾸 가부시키가이샤 | Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone |
| CN113720924A (en) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | Method for detecting content of diquafosol tetrasodium and related substances |
| WO2022107791A1 (en) * | 2020-11-18 | 2022-05-27 | 参天製薬株式会社 | Aqueous ophthalmic solution containing polyhexamethylene biguanide or salt thereof |
| JPWO2022107790A1 (en) * | 2020-11-18 | 2022-05-27 | ||
| KR102548710B1 (en) | 2020-12-24 | 2023-06-28 | 주식회사 종근당 | Pharmaceutical composition for prevention or treatment of dry eye syndrome comprising diquafosol or pharmaceutically acceptable salts thereof and tocopherol |
| CN112933040A (en) * | 2021-02-04 | 2021-06-11 | 合肥博思科创医药科技有限公司 | Preparation method of sugammadex sodium injection |
| WO2023195718A1 (en) * | 2022-04-04 | 2023-10-12 | 서울대학교산학협력단 | Composition for suppressing sweetness and method for suppressing sweetness of food |
| CN117838628B (en) * | 2024-03-01 | 2024-05-28 | 广州市桐晖药业有限公司 | Diquafosol sodium eye drops and preparation method thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH075456B2 (en) * | 1988-10-01 | 1995-01-25 | 参天製薬株式会社 | Eye drops |
| JP2530491B2 (en) | 1988-12-20 | 1996-09-04 | 参天製薬株式会社 | Hyaluronic acid eye drops |
| TW200402B (en) | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
| US5504113A (en) | 1994-03-02 | 1996-04-02 | Allergan, Inc. | Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| DK0981534T3 (en) | 1997-02-06 | 2006-09-04 | Inspire Pharmaceuticals Inc | Dinucleotides and their uses |
| BRPI9810436B1 (en) | 1997-07-25 | 2015-12-29 | Inspire Pharmaceuticals Inc | large-scale production of uridine di (5'-tetraphosphate) and salts thereof |
| KR19990074047A (en) | 1998-03-03 | 1999-10-05 | 김수복 | Cleaning, Disinfecting and Preservative Compositions for Contact Lenses |
| JP5138128B2 (en) | 1998-08-21 | 2013-02-06 | 千寿製薬株式会社 | Aqueous liquid |
| JP4880808B2 (en) * | 1999-11-15 | 2012-02-22 | 久光製薬株式会社 | Artificial tear-type eye drop composition |
| CA2413928C (en) | 2000-05-30 | 2011-01-25 | Santen Pharmaceutical Co., Ltd. | Corneal epithelial migration promoter |
| JP4003008B2 (en) | 2000-05-30 | 2007-11-07 | 参天製薬株式会社 | Corneal epithelial extension promoter |
| US6555675B2 (en) * | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| US6583181B1 (en) | 2000-11-22 | 2003-06-24 | Lonza Inc. | Antimicrobial quaternary ammonium compositions with reduced ocular irritation |
| CN1228053C (en) * | 2001-09-11 | 2005-11-23 | 参天制药株式会社 | Eye drop containing diuridine phosphoric acid |
| JP2003160491A (en) * | 2001-09-11 | 2003-06-03 | Santen Pharmaceut Co Ltd | Diuridine phosphate-containing eye drop |
| WO2003030892A1 (en) | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
| ATE381947T1 (en) | 2003-04-14 | 2008-01-15 | Wyeth Corp | COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM FOR INJECTION |
| JP4806956B2 (en) | 2004-04-20 | 2011-11-02 | 大正製薬株式会社 | Ophthalmic solution |
| US20060073172A1 (en) | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
| KR20070067189A (en) | 2004-12-02 | 2007-06-27 | 비너스 레머디스 리미티드 | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection |
| KR100870104B1 (en) * | 2005-11-28 | 2008-11-26 | 주식회사 머젠스 | Composition Having Effect on Treatment and Prevention of Dry eye syndrome |
| JP4168071B2 (en) | 2005-12-08 | 2008-10-22 | 興和株式会社 | Ophthalmic composition |
| JP2008247828A (en) | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | Aqueous medicine composition containing latanoprost |
| JP2009040727A (en) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | Stable eye lotion containing latanoprost as active ingredient |
| CN100534423C (en) * | 2007-11-30 | 2009-09-02 | 张咏梅 | Chloromycetin eyedrops with long shelf-life and preparation method thereof |
| US8119112B2 (en) | 2008-01-31 | 2012-02-21 | Bausch & Lomb Incorporated | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid |
| CN101461778A (en) * | 2009-01-06 | 2009-06-24 | 河北科技大学 | Disposable levofloxacin hydrochloride eye drops without bacteriostatic agent and preparation method thereof |
| US20100190734A1 (en) * | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
| CN102100693A (en) * | 2009-12-16 | 2011-06-22 | 沈阳兴齐制药有限公司 | Artificial tears including carnosine and preparation method thereof |
| KR20110104367A (en) | 2010-03-16 | 2011-09-22 | 삼천당제약주식회사 | Ophthalmic compositions without preservatives |
| WO2012012640A1 (en) | 2010-07-21 | 2012-01-26 | Cumberland Pharmaceuticals, Inc. | Acetycysteine compositions and methods of use thereof |
| BR112013005438B1 (en) | 2010-09-10 | 2021-09-21 | Santen Pharmaceutical Co., Ltd | AGENTS FOR THE TREATMENT OF DRYED EYE CHARACTERIZED BY COMBINING THE AGONIST OF THE P2Y2 RECEPTOR AND HYALURONIC ACID OR A SALT OF THE SAME, METHOD FOR THE TREATMENT OF DRYED EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST, AND A HOURAL ACID |
| SG10201508591UA (en) | 2010-12-28 | 2015-11-27 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate |
| CN103596572A (en) * | 2011-04-12 | 2014-02-19 | 株式会社·R-技术上野 | Aqueous ophthalmic composition |
| RU2014143008A (en) | 2012-03-26 | 2016-05-20 | Дилафор Аб | METHOD FOR TREATING STOPPING |
| MY169816A (en) * | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
-
2013
- 2013-03-25 MY MYPI2014002576A patent/MY169816A/en unknown
- 2013-03-25 WO PCT/JP2013/058519 patent/WO2013146649A1/en active Application Filing
- 2013-03-25 CN CN202110358504.0A patent/CN113018259A/en active Pending
- 2013-03-25 UA UAA201411576A patent/UA113981C2/en unknown
- 2013-03-25 DK DK13770386.4T patent/DK2832359T3/en active
- 2013-03-25 MX MX2014011468A patent/MX353874B/en active IP Right Grant
- 2013-03-25 PL PL13770386T patent/PL2832359T3/en unknown
- 2013-03-25 SG SG10201607872PA patent/SG10201607872PA/en unknown
- 2013-03-25 GE GEAP201313609A patent/GEP20166470B/en unknown
- 2013-03-25 TW TW106124911A patent/TWI692364B/en active
- 2013-03-25 EA EA201491771A patent/EA028848B1/en unknown
- 2013-03-25 BR BR112014023402-7A patent/BR112014023402B1/en not_active IP Right Cessation
- 2013-03-25 KR KR1020187037979A patent/KR20190002751A/en active Application Filing
- 2013-03-25 EP EP18193430.8A patent/EP3431092A1/en not_active Withdrawn
- 2013-03-25 KR KR1020147028142A patent/KR101536885B1/en active IP Right Review Request
- 2013-03-25 KR KR1020157004372A patent/KR101875845B1/en active IP Right Review Request
- 2013-03-25 TW TW109100132A patent/TWI723722B/en active
- 2013-03-25 TR TR2018/20073T patent/TR201820073T4/en unknown
- 2013-03-25 EP EP13770386.4A patent/EP2832359B1/en active Active
- 2013-03-25 HU HUE13770386A patent/HUE041671T2/en unknown
- 2013-03-25 ES ES13770386T patent/ES2702575T3/en active Active
- 2013-03-25 TW TW102110422A patent/TWI625135B/en active
- 2013-03-25 IN IN8632DEN2014 patent/IN2014DN08632A/en unknown
- 2013-03-25 JP JP2013062270A patent/JP5625081B2/en active Active
- 2013-03-25 PT PT13770386T patent/PT2832359T/en unknown
- 2013-03-25 TW TW109124203A patent/TWI757799B/en active
- 2013-03-25 CA CA2868390A patent/CA2868390C/en active Active
- 2013-03-25 CN CN201380016616.1A patent/CN104203254A/en active Pending
- 2013-03-25 SG SG11201405799TA patent/SG11201405799TA/en unknown
- 2013-03-25 AU AU2013241507A patent/AU2013241507A1/en not_active Abandoned
- 2013-03-25 KR KR1020187018799A patent/KR101935484B1/en active IP Right Review Request
- 2013-03-25 NZ NZ631041A patent/NZ631041A/en not_active IP Right Cessation
- 2013-03-25 US US14/386,169 patent/US9486529B2/en active Active
- 2013-03-25 KR KR1020207022714A patent/KR20200096708A/en not_active Application Discontinuation
-
2014
- 2014-04-14 JP JP2014082821A patent/JP6126041B2/en active Active
- 2014-09-01 PH PH12014501955A patent/PH12014501955A1/en unknown
-
2015
- 2015-06-08 HK HK15105452.3A patent/HK1204922A1/en unknown
- 2015-08-04 HK HK15107460.9A patent/HK1206648A1/en not_active IP Right Cessation
-
2016
- 2016-02-23 AU AU2016201111A patent/AU2016201111A1/en not_active Withdrawn
- 2016-02-23 AU AU2016201110A patent/AU2016201110B2/en not_active Ceased
- 2016-10-10 US US15/289,273 patent/US10071113B2/en active Active
-
2017
- 2017-04-05 JP JP2017075167A patent/JP6389544B2/en active Active
-
2018
- 2018-02-07 JP JP2018020154A patent/JP6483299B2/en active Active
- 2018-08-14 US US16/103,328 patent/US10632139B2/en not_active Expired - Fee Related
-
2019
- 2019-02-12 JP JP2019022692A patent/JP7042762B2/en active Active
-
2020
- 2020-03-16 US US16/819,974 patent/US11166974B2/en active Active
-
2022
- 2022-03-14 JP JP2022039183A patent/JP7447176B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08632A (en) | ||
| PH12015500115B1 (en) | Glucagon analogues | |
| PH12015500561A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| MX365950B (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis. | |
| IN2012DN03312A (en) | ||
| MX361858B (en) | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions. | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| MX370953B (en) | USE OF LEVOCETIRIZINE and MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS. | |
| MY161032A (en) | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate | |
| MX2015012315A (en) | Use of levocetirizine and montelukast in the treatment of traumatic injury. | |
| MX2015011775A (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis. | |
| SG10201909382UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| EA201492081A1 (en) | (R) -NIFURAL, ITS APPLICATION IN THE TREATMENT OF INFECTIONS AND SYNTHESIS (R) - AND (S) -NIFURAL | |
| MX2017015293A (en) | Composition for treating tissue lesions. | |
| MY182591A (en) | Compositions for use in treating eye disorders using dipyridamole | |
| NZ707081A (en) | Agent for preventing or improving decline in brain function | |
| EA033769B9 (en) | Selected amide of -hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
| PH12018501624A1 (en) | A composition comprising pic for treatment of cancer | |
| HK1198632A1 (en) | Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field no- | |
| EP2886112A4 (en) | Composition for preventing or treating eye diseases, containing s-allyl-l-cysteine as active ingredient, and pharmaceutical formulation containing same | |
| PH12015500070B1 (en) | Pediatric oral liquid compositions containing nepadutant | |
| NZ631362A (en) | Arry-520 for use in treating cancer in a patient with low aag | |
| TH157373A (en) | Ophthalmic solutions containing dikvaphosol |